Atrial Septal Defect (ASD) is a congenital heart condition characterized by an abnormal opening between the upper two chambers of the heart, the atria. This opening, known as the septum, fails to close properly during fetal development, leading to a passage between the left and right atria. ASD can vary in size, and its impact on heart function depends on the size and location of the defect. In many cases, small ASDs may not cause noticeable symptoms and can go undetected for years. However, larger defects can potentially lead to complications, including an increased risk of developing heart-related issues such as arrhythmias, pulmonary hypertension, or stroke. Diagnosis often involves a combination of physical examinations, imaging tests, and echocardiograms. Treatment options range from monitoring for small, asymptomatic defects to more proactive interventions, such as surgical repair or catheter-based procedures, for larger or symptomatic cases. Advances in medical technology and treatment options have significantly improved the outlook for individuals with ASD, allowing for timely and effective management of this congenital heart condition. Regular follow-up care is essential to monitor heart health and address any potential complications, ensuring individuals with ASD can lead healthy and fulfilling lives
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India